Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The two blockbusters Novo Nordisk medicines are among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

WASHINGTON -- Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

According to CMS, close to 2.3 million seniors enrolled in Medicare are using Novo Nordisk’s semaglutide medications branded as Ozempic, Wegovy and Rybelsus. Between November 2023 and October ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

(AP Photo/Amanda Andrade-Rhoades, File)(Amanda Andrade-Rhoades / AP) WASHINGTON — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...